# Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)

> **NCT07166211** · PHASE2 · RECRUITING · sponsor: **Keymed Biosciences Co.Ltd** · enrollment: 48 (estimated)

## Conditions studied

- Chronic Spontaneous Urticaria (CSU)

## Interventions

- **BIOLOGICAL:** CM512 injection
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT07166211
- **Lead sponsor:** Keymed Biosciences Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-27
- **Primary completion:** 2026-11-02
- **Final completion:** 2027-01-14
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07166211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07166211, "Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT07166211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*